Hypertension · 2012 · 119 citations · 29 references
Life SciencesCardiologyPhysiologyCell SignalingInflammationSignal TransductionCardiac BiomarkersCardiac PhysiologyCardiovascular DiseaseFibrosisInflammatory SignalingCardiac Fibrosis ModulationCardiac RemodelingCardiac Systolic FunctionFibrosis-associated CytokinesMatrix Metalloproteinase 9 GeneticsMineralocorticoid Receptor SignalingMineralocorticoid ReceptorsProinflammatory Mediators
Because the role of mineralocorticoid receptors in specific cell types in cardiac remodeling remains unknown, we have compared cardiac responses with deoxycorticosterone/salt in cardiomyocyte mineralocorticoid receptor-null (MyoMRKO) and wild-type (WT) mice at 8 days and 8 weeks. No differences in cardiac function between untreated WT and MyoMRKO mice were found, whereas profibrotic markers were reduced in MyoMRKO hearts at baseline. At 8 days, MyoMRKO showed monocyte/macrophage recruitment equivalent to WT mice in response to deoxycorticosterone/salt but a suppression of markers of fibrosis compared with WT. At 8 weeks, MyoMRKO mice showed no deoxycorticosterone/salt-induced increase in inflammatory cell infiltration and collagen deposition or in proinflammatory gene expression. Although some profibrotic markers were equivalently increased in both genotypes, MyoMRKO mice also showed increased baseline levels of mRNA and protein for the transforming growth factor-β/connective tissue growth factor inhibitor decorin compared with WT that was accompanied by higher levels of matrix metalloproteinase 2/matrix metalloproteinase 9 activity. These data point to a direct role for cardiomyocyte mineralocorticoid receptor in both deoxycorticosterone/salt-induced tissue inflammation and remodeling and suggest potential mechanisms for the cardioprotective effects of selective mineralocorticoid receptor blockade in cardiomyocytes that may involve regulation of matrix metalloproteinase 2/matrix metalloproteinase 9 activity and the transforming growth factor-β-connective tissue growth factor profibrotic pathway.
29
Melinda Fitzgerald, Ian P. Hayward, Anita C. Thomas et al. · 1995 · 2.6K citations
Mineralocorticoids, hypertension, and cardiac fibrosis.
Morag J. Young, M Fullerton, Rodney J. Dilley et al. · Journal of Clinical Investigation · 1994 · 437 citations · Full text
Amanda J. Rickard, James J. Morgan, Greg H. Tesch et al. · Hypertension · 2009 · 296 citations · Full text